Quitting deserves medicine.
We’re developing it.

Most people who smoke or vape want to stop. But fewer than 1 in 10 who smoke succeed each year.¹ That isn’t a failure of resolve. It’s a gap in medicine, and AchieveRx is a late-stage specialty pharmaceutical company working to close it.

Meet The Quit Company.

Who We Are

THE MEDICAL NEED

Most people who smoke want to quit.
Few get the help to do it.

Tobacco use remains the leading cause of preventable death and disease in the U.S.²

Half of people who smoke try to quit each year.¹

12 types of cancer
linked to smoking²
$600B+ in annual US costs
from smoking⁵
25M adults in the US
smoke cigarettes³
18M adults in the US
use e-cigarettes³
16M+ Americans living with a
smoking-related disease²
7M+ deaths worldwide each year
from tobacco use, including
an estimated 1.6M people
exposed to secondhand smoke⁴

Quitting has been shown to…

add as much as a decade to life⁶
lower the risk of heart disease, COPD, and 12 types of cancer⁶
reduce complications after surgery⁷
help even after a diagnosis of heart disease or COPD, and improve survival after a cancer diagnosis^6,8

It’s never too late to quit.

OUR APPROACH

It’s chemistry,
not character.

Nicotine dependence is an addiction rooted in the brain. Nicotine binds to nicotinic receptors and changes how they respond over time, which makes it harder to quit. We’re developing cytisinicline, an investigational treatment that binds to those same receptors. If approved, it would be the first new medicine approved by the FDA for quitting smoking in 20 years.⁹